Advancing ADC Therapeutics in Oncology

Expert Support for ADC Drug Development, Driving Success from Lab to Clinic

TD2 is a scientifically driven CRO focused on the development of novel cancer treatments including the development of antibody drug conjugate (ADC) therapies in oncology. Our comprehensive range of services includes preclinical testing, regulatory compliance assistance, and management of early phase clinical trials. TD2 equips biotech and pharmaceutical companies with the necessary tools and expertise to advance their ADC therapeutic candidates from initial discovery to clinical evaluation. Utilizing advanced technologies and our collaborative approach, we ensure that our partners meet critical milestones in their drug development process. TD2 is strategically positioned to support the progression of innovative ADC therapies, aiming to improve treatment outcomes and enhance patient quality of life.

Advancing ADC Therapeutics in Oncology

Features and Benefits:

  • Translational services to support development from the preclinical stage through early phase clinical trials
  • Experienced drug development team with deep clinical and scientific knowledge
  • Regulatory and Toxicology Experts in ADC Therapeutics

Request more information about our ADC Evaluation Services

Preclinical Services:

TD2 offers specialized preclinical services for advancing ADC therapies in oncology, covering both in vitro and in vivo studies. Our in vitro services include comprehensive assays for characterizing ADCs, such as antigen expression, binding studies, and cytotoxicity assessments. In vivo services include pharmacology studies using over 300 cancer models and advanced imaging techniques to optimize ADC development. This integrated approach ensures robust support for translating ADC research from the lab to clinical trials.

In Vitro Characterization

In Vitro
Characterization

Protein expression via western blotx

ADC Binding via flow cytometryx

Gene and protein expression via flow and qPCRx

In vitro activity assays by colony formation assay (CFA)x

Tumor penetration assaysx

Flow analysis of cytotoxicity, DNA damage, cell cycle and apoptosisx

Determination of cellular toxicity in response to ADCx

Full PK evaluation services

Payload analysis from Plasma Stability analysis

In Vivo Pharmacology

In Vivo
Pharmacology

In vivo efficacy studiesx

Specialty surgical & orthotopic modelsx

Over 300+ CDX modelsx

Immuno-oncology

Glioblastoma

DMPK analytical services

PK evaluation

Optical Imaging

Metabolomic and Proteomic analysis

Comprehensive Flow Cytometry Services

Regulatory Support:

TD2 offers comprehensive regulatory support to expedite the development of Antibody Drug Conjugates (ADCs) for cancer therapies. With a team skilled in oncology-focused medical writing, regulatory expertise in Chemistry, Manufacturing, and Controls (CMC), as well as pharmacology and toxicology, TD2 provides a tailored approach to navigate complex regulatory landscapes. Our services encompass strategic consultation, program management, and direct FDA liaison activities, ensuring that each step of the ADC development process aligns with regulatory requirements to accelerate time to market.

Clinical Trial Management Services:

TD2’s clinical study management services are designed to support the advancement of ADC cancer treatments through the clinical trial phase. TD2 offers a comprehensive portfolio program management including study design, patient recruitment, data management, and site engagement. Our approach utilizes advanced technology and personalized strategies to ensure efficient trial progression. TD2 also focuses on robust program analysis and strategic consultation to navigate complex regulatory requirements, aiming to optimize trial outcomes and speed up the introduction of new cancer therapies to the market.

Our Full Scope Of Clinical Trial Services

Comprehensive

Clinical Trial Services Include:

Additional Resources

Top Trends in ADC Drug Development

Preclinical

Top Trends in ADC Drug Development

GET STARTED

Work with a team who believes in your research as much as you do.

Are you ready to start your ADC therapy studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.

Get Started Now

×

Protein expression via western blot

Protein expression via western blot

Changes in phosphorylation of Cofillin in three cancer cell lines

×

ADC Binding via flow cytometry

ADC Binding via flow cytometry

Sacituzumab binding affinity and EC50 determination

×

Gene and protein expression via flow and qPCR

Gene and protein expression via flow and qPCR

×

In vitro activity assays by colony formation assay (CFA)

In vitro activity assays by colony formation assay (CFA)

×

Tumor penetration assays

Tumor penetration assays

×

Flow analysis of cytotoxicity, DNA damanage, cell cycle and apoptosis

Flow analysis of cytotoxicity, DNA damanage, cell cycle and apoptosis

×

Determination of cellular toxicity in response to ADC

Determination of cellular toxicity in response to ADC

×

In vivo efficacy studies

In vivo efficacy studies

×

Specialty surgical & orthotopic models

Syngeneic Lines
Intrabladder MBT-2, MB49
Intracranial GL261
Intrahepatic CT-26-luc
Intrarenal RENCA
Intrapancreatic Pano2
Intrathoracic LL2-luc (In development)
Mammary Fat Pad 4T1, 4T1-luc, EMT6, E0771
Ovarian Ascites ID8-luc
IP Disseminated Colon-26-luc
IV Disseminated B16-F10-luc

Xenograft Lines
Intracranial BT-142, BT-474-luc, U251, U251-luc,
U87-MG, U87-MG-luc, NCI-H1975-luc,
GMB-PDX
Intrahepatic Hep3B, Huh-7-luc
Intrapancreatic BxPC3, BxPC3-luc, AsPC-1, AsPC-1-fluc,
Panc-1-luc, HPAF-II-luc
Intrathoracic NCI-H460-luc
IP Disseminated HCT-116-luc, SK-OV-3-luc, Cal-27-fluc,
OVCAR-8
Mammary Fat Pad BT-474, HCC70, MDA-MB-231,
MDA-MB-231-luc
Ovarian Ascites A2780, A2780CP, ES-2, OVCAR-8